December 18, 2024
On December 17, 2024, Percheron Therapeutics announced topline six-month results from the Company’s ongoing international phase IIb randomised, placebo-controlled trial of avicursen (ATL1102) in non-ambulant boys with Duchenne muscular dystrophy (DMD).
To read their full press release, please click here.
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
